We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA did not believe the company provided enough clinical evidence to support the expanded indication, as the system had not met the primary endpoints of its sebaceous hyperplasia study. Read More